Role of hyaluronan in pancreatic cancer biology and therapy: Once again in the spotlight

Cancer Science

Volumn 107, Issue 5, 2016, Pages 569-575

  Sato, Norihiro ^a   Kohi, Shiro ^a   Hirata, Keiji ^a   Goggins, Michael ^b  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Desmoplasia; Hyaluronan; Pancreatic ductal adenocarcinoma; Tumor stroma; Tumor stroma interaction

Indexed keywords

ANTINEOPLASTIC AGENT; DNA METHYLTRANSFERASE; HERMES ANTIGEN; RECOMBINANT HYALURONIDASE; HYALURONIC ACID;

ANGIOGENESIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER THERAPY; CELL FUNCTION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURFACE; DISEASE COURSE; HUMAN; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE; TREATMENT OUTCOME; ANIMAL; BIOSYNTHESIS; CARCINOMA, PANCREATIC DUCTAL; CELL TRANSFORMATION; METABOLISM; PANCREATIC NEOPLASMS; PATHOLOGY;

ANIMALS; ANTIGENS, CD44; CARCINOMA, PANCREATIC DUCTAL; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; HUMANS; HYALURONIC ACID; PANCREATIC NEOPLASMS;

EID: 84961185769     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12913     Document Type: Review

References (99)

1. Hidalgo M. Pancreatic cancer. N Engl J Med 2010; 362: 1605-17.
2. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002; 2: 897-909.
3. Sato N, Goggins M. The role of epigenetic alterations in pancreatic cancer. J Hepatobiliary Pancreat Surg 2006; 13: 286-95.
4. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet 2011; 378: 607-20.
5. Rowe RG, Weiss SJ. Navigating ECM barriers at the invasive front: the cancer cell-stroma interface. Annu Rev Cell Dev Biol 2009; 25: 567-95.
6. Mahadevan D, Von Hoff DD. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 2007; 6: 1186-97.
7. Whatcott C, Han H, Posner RG, Von Hoff DD. Tumor-stromal interactions in pancreatic cancer. Crit Rev Oncog 2013; 18: 135-51.
8. Itano N, Zhuo L, Kimata K. Impact of the hyaluronan-rich tumor microenvironment on cancer initiation and progression. Cancer Sci 2008; 99: 1720-5.
9. Sironen RK, Tammi M, Tammi R, Auvinen PK, Anttila M, Kosma VM. Hyaluronan in human malignancies. Exp Cell Res 2011; 317: 383-91.
10. Mahlbacher V, Sewing A, Elsasser HP, Kern HF. Hyaluronan is a secretory product of human pancreatic adenocarcinoma cells. Eur J Cell Biol 1992; 58: 28-34.
11. Fries H, Elsasser HP, Mahlbacher V, Neumann K, Kern HF. Localisation of hyaluronate (HA) in primary tumors and nude mouse xenografts of human pancreatic carcinomas using a biotinylated HA-binding protein. Virchows Arch 1994; 424: 7-12.
12. Abetamann V, Kern HF, Elsasser HP. Differential expression of the hyaluronan receptors CD44 and RHAMM in human pancreatic cancer cells. Clin Cancer Res 1996; 2: 1607-18.
13. Theocharis AD, Tsara ME, Papageorgacopoulou N, Karavias DD, Theocharis DA. Pancreatic carcinoma is characterized by elevated content of hyaluronan and chondroitin sulfate with altered disaccharide composition. Biochim Biophys Acta 2000; 1502: 201-6.
14. Whatcott CJ, Diep CH, Jiang P et al. Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer. Clin Cancer Res 2015; 21: 3561-8.
15. Cheng XB, Sato N, Kohi S, Yamaguchi K. Prognostic impact of hyaluronan and its regulators in pancreatic ductal adenocarcinoma. PLoS ONE 2013; 8: e80765.
16. Li XP, Zhang XW, Zheng LZ, Guo WJ. Expression of CD44 in pancreatic cancer and its significance. Int J Clin Exp Pathol 2015; 8: 6724-31.
17. Cheng XB, Sato N, Kohi S, Koga A, Hirata K. Receptor for hyaluronic acid-mediated motility is associated with poor survival in pancreatic ductal adenocarcinoma. J Cancer 2015; 6: 1093-8.
18. Kultti A, Zhao C, Singha NC et al. Accumulation of extracellular hyaluronan by hyaluronan synthase 3 promotes tumor growth and modulates the pancreatic cancer microenvironment. Biomed Res Int 2014; 2014: 817613.
19. Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 2004; 4: 528-39.
20. Csoka AB, Frost GI, Stern R. The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol 2001; 20: 499-508.
21. Stern R. Hyaluronan catabolism: a new metabolic pathway. Eur J Cell Biol 2004; 83: 317-25.
22. Lepperdinger G, Mullegger J, Kreil G. Hyal2-less active, but more versatile? Matrix Biol 2001; 20: 509-14.
23. Harada H, Takahashi M. CD44-dependent intracellular and extracellular catabolism of hyaluronic acid by hyaluronidase-1 and -2. J Biol Chem 2007; 282: 5597-607.
24. Misra S, Hascall VC, Markwald RR, Ghatak S. Interactions between hyaluronan and its receptors (CD44, RHAMM) regulate the activities of inflammation and cancer. Front Immunol 2015; 6: 201.
25. Haynes BF, Liao HX, Patton KL. The transmembrane hyaluronate receptor (CD44): multiple functions, multiple forms. Cancer Cells 1991; 3: 347-50.
26. Misra S, Heldin P, Hascall VC et al. Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J 2011; 278: 1429-43.
27. Maxwell CA, McCarthy J, Turley E. Cell-surface and mitotic-spindle RHAMM: moonlighting or dual oncogenic functions? J Cell Sci 2008; 121: 925-32.
28. Tammi RH, Kultti A, Kosma VM, Pirinen R, Auvinen P, Tammi MI. Hyaluronan in human tumors: pathobiological and prognostic messages from cell-associated and stromal hyaluronan. Semin Cancer Biol 2008; 18: 288-95.
29. Ropponen K, Tammi M, Parkkinen J et al. Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. Cancer Res 1998; 58: 342-7.
30. Setala LP, Tammi MI, Tammi RH et al. Hyaluronan expression in gastric cancer cells is associated with local and nodal spread and reduced survival rate. Br J Cancer 1999; 79: 1133-8.
31. Auvinen P, Tammi R, Parkkinen J et al. Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol 2000; 156: 529-36.
32. Anttila MA, Tammi RH, Tammi MI, Syrjanen KJ, Saarikoski SV, Kosma VM. High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer. Cancer Res 2000; 60: 150-5.
33. Koyama H, Hibi T, Isogai Z et al. Hyperproduction of hyaluronan in neu-induced mammary tumor accelerates angiogenesis through stromal cell recruitment: possible involvement of versican/PG-M. Am J Pathol 2007; 170: 1086-99.
34. Kosaki R, Watanabe K, Yamaguchi Y. Overproduction of hyaluronan by expression of the hyaluronan synthase Has2 enhances anchorage-independent growth and tumorigenicity. Cancer Res 1999; 59: 1141-5.
35. Liu N, Gao F, Han Z, Xu X, Underhill CB, Zhang L. Hyaluronan synthase 3 overexpression promotes the growth of TSU prostate cancer cells. Cancer Res 2001; 61: 5207-14.
36. Simpson MA, Wilson CM, McCarthy JB. Inhibition of prostate tumor cell hyaluronan synthesis impairs subcutaneous growth and vascularization in immunocompromised mice. Am J Pathol 2002; 161: 849-57.
37. Kim HR, Wheeler MA, Wilson CM et al. Hyaluronan facilitates invasion of colon carcinoma cells in vitro via interaction with CD44. Cancer Res 2004; 64: 4569-76.
38. Itano N, Atsumi F, Sawai T et al. Abnormal accumulation of hyaluronan matrix diminishes contact inhibition of cell growth and promotes cell migration. Proc Natl Acad Sci U S A 2002; 99: 3609-14.
39. Zoltan-Jones A, Huang L, Ghatak S, Toole BP. Elevated hyaluronan production induces mesenchymal and transformed properties in epithelial cells. J Biol Chem 2003; 278: 45801-10.
40. Toole BP, Zoltan-Jones A, Misra S, Ghatak S. Hyaluronan: a critical component of epithelial-mesenchymal and epithelial-carcinoma transitions. Cells Tissues Organs 2005; 179: 66-72.
41. Tian X, Azpurua J, Hine C et al. High-molecular-mass hyaluronan mediates the cancer resistance of the naked mole rat. Nature 2013; 499: 346-9.
42. Fuchs K, Hippe A, Schmaus A, Homey B, Sleeman JP, Orian-Rousseau V. Opposing effects of high- and low-molecular weight hyaluronan on CXCL12-induced CXCR4 signaling depend on CD44. Cell Death Dis 2013; 4: e819.
43. Bourguignon LY, Spevak CC, Wong G, Xia W, Gilad E. Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the Production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J Biol Chem 2009; 284: 26533-46.
44. Bourguignon LY, Wong G, Earle C, Krueger K, Spevak CC. Hyaluronan-CD44 interaction promotes c-Src-mediated twist signaling, microRNA-10b expression, and RhoA/RhoC up-regulation, leading to Rho-kinase-associated cytoskeleton activation and breast tumor cell invasion. J Biol Chem 2010; 285: 36721-35.
45. West DC, Kumar S. Hyaluronan and angiogenesis. Ciba Found Symp 1989; 143: 187-201; discussion-7, 81-5.
46. Wu M, Cao M, He Y et al. A novel role of low molecular weight hyaluronan in breast cancer metastasis. FASEB J 2015; 29: 1290-8.
47. Schmaus A, Klusmeier S, Rothley M et al. Accumulation of small hyaluronan oligosaccharides in tumour interstitial fluid correlates with lymphatic invasion and lymph node metastasis. Br J Cancer 2014; 111: 559-67.
48. Cheng XB, Kohi S, Koga A, Hirata K, Sato N. Hyaluronan stimulates pancreatic cancer cell motility. Oncotarget 2015. doi: 10.18632/oncotarget.6617
49. Jacobetz MA, Chan DS, Neesse A et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 2012; 62: 112-20.
50. Takada M, Yamamoto M, Saitoh Y. The significance of CD44 in human pancreatic cancer: II. The role of CD44 in human pancreatic adenocarcinoma invasion. Pancreas 1994; 9: 753-7.
51. Immervoll H, Hoem D, Steffensen OJ, Miletic H, Molven A. Visualization of CD44 and CD133 in normal pancreas and pancreatic ductal adenocarcinomas: non-overlapping membrane expression in cell populations positive for both markers. J Histochem Cytochem 2011; 59: 441-55.
52. Satoh K, Shimosegawa T, Koizumi M, Toyota T. Expression of CD44 in duct cell carcinomas and in intraductal neoplasms of the pancreas. Anticancer Res 1997; 17: 215-9.
53. Castella EM, Ariza A, Ojanguren I et al. Differential expression of CD44v6 in adenocarcinoma of the pancreas: an immunohistochemical study. Virchows Arch 1996; 429: 191-5.
54. Gotoda T, Matsumura Y, Kondo H et al. Expression of CD44 variants and its association with survival in pancreatic cancer. Jpn J Cancer Res 1998; 89: 1033-40.
55. Teranishi F, Takahashi N, Gao N et al. Phosphoinositide 3-kinase inhibitor (wortmannin) inhibits pancreatic cancer cell motility and migration induced by hyaluronan in vitro and peritoneal metastasis in vivo. Cancer Sci 2009; 100: 770-7.
56. Adamia S, Maxwell CA, Pilarski LM. Hyaluronan and hyaluronan synthases: potential therapeutic targets in cancer. Curr Drug Targets Cardiovasc Haematol Disord 2005; 5: 3-14.
57. Itano N, Sawai T, Atsumi F et al. Selective expression and functional characteristics of three mammalian hyaluronan synthases in oncogenic malignant transformation. J Biol Chem 2004; 279: 18679-87.
58. Yamada Y, Itano N, Narimatsu H et al. Elevated transcript level of hyaluronan synthase1 gene correlates with poor prognosis of human colon cancer. Clin Exp Metastasis 2004; 21: 57-63.
59. Yabushita H, Noguchi M, Kishida T et al. Hyaluronan synthase expression in ovarian cancer. Oncol Rep 2004; 12: 739-43.
60. Kramer MW, Escudero DO, Lokeshwar SD et al. Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis. Cancer 2011; 117: 1197-209.
61. Chi A, Shirodkar SP, Escudero DO et al. Molecular characterization of kidney cancer: association of hyaluronic acid family with histological subtypes and metastasis. Cancer 2012; 118: 2394-402.
62. Auvinen P, Rilla K, Tumelius R et al. Hyaluronan synthases (HAS1-3) in stromal and malignant cells correlate with breast cancer grade and predict patient survival. Breast Cancer Res Treat 2014; 143: 277-86.
63. Kohi S, Sato N, Cheng XB, Koga A, Higure A, Hirata K. A novel epigenetic mechanism regulating hyaluronan production in pancreatic cancer cells. Clin Exp Metastasis 2016; 33: 225-30.
64. Gao J, Wang L, Xu J et al. Aberrant DNA methyltransferase expression in pancreatic ductal adenocarcinoma development and progression. J Exp Clin Cancer Res 2013; 32: 86.
65. Peng DF, Kanai Y, Sawada M et al. Increased DNA methyltransferase 1 (DNMT1) protein expression in precancerous conditions and ductal carcinomas of the pancreas. Cancer Sci 2005; 96: 403-8.
66. Sato N, Maehara N, Su GH, Goggins M. Effects of 5-aza-2′-deoxycytidine on matrix metalloproteinase expression and pancreatic cancer cell invasiveness. J Natl Cancer Inst 2003; 95: 327-30.
67. Sato N, Maitra A, Fukushima N et al. Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Res 2003; 63: 4158-66.
68. Knudson W, Biswas C, Toole BP. Interactions between human tumor cells and fibroblasts stimulate hyaluronate synthesis. Proc Natl Acad Sci U S A 1984; 81: 6767-71.
69. Sato N, Maehara N, Goggins M. Gene expression profiling of tumor-stromal interactions between pancreatic cancer cells and stromal fibroblasts. Cancer Res 2004; 64: 6950-6.
70. Nagy N, Kuipers HF, Frymoyer AR et al. 4-methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy in inflammation, autoimmunity, and cancer. Front Immunol 2015; 6: 123.
71. Kultti A, Pasonen-Seppanen S, Jauhiainen M et al. 4-Methylumbelliferone inhibits hyaluronan synthesis by depletion of cellular UDP-glucuronic acid and downregulation of hyaluronan synthase 2 and 3. Exp Cell Res 2009; 315: 1914-23.
72. Kakizaki I, Kojima K, Takagaki K et al. A novel mechanism for the inhibition of hyaluronan biosynthesis by 4-methylumbelliferone. J Biol Chem 2004; 279: 33281-9.
73. Yoshihara S, Kon A, Kudo D et al. A hyaluronan synthase suppressor, 4-methylumbelliferone, inhibits liver metastasis of melanoma cells. FEBS Lett 2005; 579: 2722-6.
74. Urakawa H, Nishida Y, Wasa J et al. Inhibition of hyaluronan synthesis in breast cancer cells by 4-methylumbelliferone suppresses tumorigenicity in vitro and metastatic lesions of bone in vivo. Int J Cancer 2012; 130: 454-66.
75. Twarock S, Freudenberger T, Poscher E et al. Inhibition of oesophageal squamous cell carcinoma progression by in vivo targeting of hyaluronan synthesis. Mol Cancer 2011; 10: 30.
76. Piccioni F, Malvicini M, Garcia MG et al. Antitumor effects of hyaluronic acid inhibitor 4-methylumbelliferone in an orthotopic hepatocellular carcinoma model in mice. Glycobiology 2012; 22: 400-10.
77. Morohashi H, Kon A, Nakai M et al. Study of hyaluronan synthase inhibitor, 4-methylumbelliferone derivatives on human pancreatic cancer cell (KP1-NL). Biochem Biophys Res Commun 2006; 345: 1454-9.
78. Hajime M, Shuichi Y, Makoto N et al. Inhibitory effect of 4-methylesculetin on hyaluronan synthesis slows the development of human pancreatic cancer in vitro and in nude mice. Int J Cancer 2007; 120: 2704-9.
79. Nakazawa H, Yoshihara S, Kudo D et al. 4-methylumbelliferone, a hyaluronan synthase suppressor, enhances the anticancer activity of gemcitabine in human pancreatic cancer cells. Cancer Chemother Pharmacol 2006; 57: 165-70.
80. Ricciardelli C, Ween MP, Lokman NA, Tan IA, Pyragius CE, Oehler MK. Chemotherapy-induced hyaluronan production: a novel chemoresistance mechanism in ovarian cancer. BMC Cancer 2013; 13: 476.
81. Yates TJ, Lopez LE, Lokeshwar SD et al. Dietary supplement 4-methylumbelliferone: an effective chemopreventive and therapeutic agent for prostate cancer. J Natl Cancer Inst 2015; 107: djv085.
82. Banerjee S, Thayanithy V, Sangwan V, Mackenzie TN, Saluja AK, Subramanian S. Minnelide reduces tumor burden in preclinical models of osteosarcoma. Cancer Lett 2013; 335: 412-20.
83. Banerjee S, Modi S, McGinn O et al. Impaired synthesis of stromal components in response to Minnelide improves vascular function, drug delivery and survival in pancreatic cancer. Clin Cancer Res 2015; 22: 415-25.
84. Toole BP. Hyaluronan-CD44 interactions in cancer: paradoxes and possibilities. Clin Cancer Res 2009; 15: 7462-8.
85. Lennon FE, Mirzapoiazova T, Mambetsariev N, Mambetsariev B, Salgia R, Singleton PA. Transactivation of the receptor-tyrosine kinase ephrin receptor A2 is required for the low molecular weight hyaluronan-mediated angiogenesis that is implicated in tumor progression. J Biol Chem 2014; 289: 24043-58.
86. Chanmee T, Ontong P, Kimata K, Itano N. Key roles of hyaluronan and its CD44 receptor in the stemness and survival of cancer stem cells. Front Oncol 2015; 5: 180.
87. Jiang W, Zhang Y, Kane KT et al. CD44 regulates pancreatic cancer invasion through MT1-MMP. Mol Cancer Res 2015; 13: 9-15.
88. Li L, Hao X, Qin J et al. Antibody against CD44s inhibits pancreatic tumor initiation and postradiation recurrence in mice. Gastroenterology 2014; 146: 1108-18.
89. Molejon MI, Tellechea JI, Loncle C et al. Deciphering the cellular source of tumor relapse identifies CD44 as a major therapeutic target in pancreatic adenocarcinoma. Oncotarget 2015; 6: 7408-23.
90. Sohara Y, Ishiguro N, Machida K et al. Hyaluronan activates cell motility of v-Src-transformed cells via Ras-mitogen-activated protein kinase and phosphoinositide 3-kinase-Akt in a tumor-specific manner. Mol Biol Cell 2001; 12: 1859-68.
91. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012; 21: 418-29.
92. Whatcott CJ, Han H, Posner RG, Hostetter G, Von Hoff DD. Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look. Cancer Discov 2011; 1: 291-6.
93. Yu M, Tannock IF. Targeting tumor architecture to favor drug penetration: a new weapon to combat chemoresistance in pancreatic cancer? Cancer Cell 2012; 21: 327-9.
94. Provenzano PP, Hingorani SR. Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer. Br J Cancer 2013; 108: 1-8.
95. Von Hoff DD, Ervin T, Arena FP et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691-703.
96. Shepard HM. Breaching the castle walls: hyaluronan depletion as a therapeutic approach to cancer therapy. Front Oncol 2015; 5: 192.
97. Thompson CB, Shepard HM, O'Connor PM et al. Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. Mol Cancer Ther 2010; 9: 3052-64.
98. Singha NC, Nekoroski T, Zhao C et al. Tumor-associated hyaluronan limits efficacy of monoclonal antibody therapy. Mol Cancer Ther 2015; 14: 523-32.
99. Manuel ER, Chen J, D'Apuzzo M et al. Salmonella-based therapy targeting indoleamine 2, 3-dioxygenase coupled with enzymatic depletion of tumor hyaluronan induces complete regression of aggressive pancreatic tumors. Cancer Immunol Res 2015; 3: 1096-107.